U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Platinum-Resistant Malignant Female Reproductive System Neoplasm

MedGen UID:
1715782
•Concept ID:
C5239315
•
Neoplastic Process

Definition

A malignant female reproductive system neoplasm that progresses between one and six months of completing the last platinum therapy. [from NCI]

Professional guidelines

PubMed

Treatment Approaches for Platinum-Resistant Ovarian Cancer.
St Laurent J, Liu JF
J Clin Oncol 2024 Jan 10;42(2):127-133. Epub 2023 Nov 1 doi: 10.1200/JCO.23.01771. PMID: 37910841
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.
Richardson DL, Eskander RN, O'Malley DM
JAMA Oncol 2023 Jun 1;9(6):851-859. doi: 10.1001/jamaoncol.2023.0197. PMID: 37079311
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A, Ryan N, Wiggans AJ, Rogozińska E, Morrison J
Cochrane Database Syst Rev 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4. PMID: 35170751Free PMC Article

Recent clinical studies

Etiology

Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, Matulonis U, O'Malley D, Raspagliesi F, Scambia G, Monk BJ
Int J Gynecol Cancer 2024 Apr 1;34(4):469-477. doi: 10.1136/ijgc-2023-004924. PMID: 38101816
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.
Dilawari A, Shah M, Ison G, Gittleman H, Fiero MH, Shah A, Hamed SS, Qiu J, Yu J, Manheng W, Ricks TK, Pragani R, Arudchandran A, Patel P, Zaman S, Roy A, Kalavar S, Ghosh S, Pierce WF, Rahman NA, Tang S, Mixter BD, Kluetz PG, Pazdur R, Amiri-Kordestani L
Clin Cancer Res 2023 Oct 2;29(19):3835-3840. doi: 10.1158/1078-0432.CCR-23-0991. PMID: 37212825Free PMC Article
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A, Ryan N, Wiggans AJ, Rogozińska E, Morrison J
Cochrane Database Syst Rev 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4. PMID: 35170751Free PMC Article
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.
Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K
JAMA Oncol 2021 Jan 1;7(1):78-85. doi: 10.1001/jamaoncol.2020.5945. PMID: 33211063Free PMC Article
"Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?
Davis A, Tinker AV, Friedlander M
Gynecol Oncol 2014 Jun;133(3):624-31. Epub 2014 Mar 4 doi: 10.1016/j.ygyno.2014.02.038. PMID: 24607285

Diagnosis

Treatment Approaches for Platinum-Resistant Ovarian Cancer.
St Laurent J, Liu JF
J Clin Oncol 2024 Jan 10;42(2):127-133. Epub 2023 Nov 1 doi: 10.1200/JCO.23.01771. PMID: 37910841
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.
Dilawari A, Shah M, Ison G, Gittleman H, Fiero MH, Shah A, Hamed SS, Qiu J, Yu J, Manheng W, Ricks TK, Pragani R, Arudchandran A, Patel P, Zaman S, Roy A, Kalavar S, Ghosh S, Pierce WF, Rahman NA, Tang S, Mixter BD, Kluetz PG, Pazdur R, Amiri-Kordestani L
Clin Cancer Res 2023 Oct 2;29(19):3835-3840. doi: 10.1158/1078-0432.CCR-23-0991. PMID: 37212825Free PMC Article
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.
Richardson DL, Eskander RN, O'Malley DM
JAMA Oncol 2023 Jun 1;9(6):851-859. doi: 10.1001/jamaoncol.2023.0197. PMID: 37079311
Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.
Havasi A, Cainap SS, Havasi AT, Cainap C
Medicina (Kaunas) 2023 Mar 10;59(3) doi: 10.3390/medicina59030544. PMID: 36984544Free PMC Article
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.
Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K
JAMA Oncol 2021 Jan 1;7(1):78-85. doi: 10.1001/jamaoncol.2020.5945. PMID: 33211063Free PMC Article

Therapy

Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.
Richardson DL, Eskander RN, O'Malley DM
JAMA Oncol 2023 Jun 1;9(6):851-859. doi: 10.1001/jamaoncol.2023.0197. PMID: 37079311
Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.
Havasi A, Cainap SS, Havasi AT, Cainap C
Medicina (Kaunas) 2023 Mar 10;59(3) doi: 10.3390/medicina59030544. PMID: 36984544Free PMC Article
Targeting NaPi2b in ovarian cancer.
Banerjee S, Drapkin R, Richardson DL, Birrer M
Cancer Treat Rev 2023 Jan;112:102489. Epub 2022 Nov 14 doi: 10.1016/j.ctrv.2022.102489. PMID: 36446254
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, Konecny GE, Banerjee S, Murphy CG, Tanyi JL, Hirte H, Konner JA, Lim PC, Prasad-Hayes M, Monk BJ, Pautier P, Wang J, Berkenblit A, Vergote I, Birrer MJ
Ann Oncol 2021 Jun;32(6):757-765. Epub 2021 Mar 2 doi: 10.1016/j.annonc.2021.02.017. PMID: 33667670
"Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?
Davis A, Tinker AV, Friedlander M
Gynecol Oncol 2014 Jun;133(3):624-31. Epub 2014 Mar 4 doi: 10.1016/j.ygyno.2014.02.038. PMID: 24607285

Prognosis

Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.
Richardson DL, Eskander RN, O'Malley DM
JAMA Oncol 2023 Jun 1;9(6):851-859. doi: 10.1001/jamaoncol.2023.0197. PMID: 37079311
Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.
Havasi A, Cainap SS, Havasi AT, Cainap C
Medicina (Kaunas) 2023 Mar 10;59(3) doi: 10.3390/medicina59030544. PMID: 36984544Free PMC Article
CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype.
Li H, Luo F, Jiang X, Zhang W, Xiang T, Pan Q, Cai L, Zhao J, Weng D, Li Y, Dai Y, Sun F, Yang C, Huang Y, Yang J, Tang Y, Han Y, He M, Zhang Y, Song L, Xia JC
J Immunother Cancer 2022 Mar;10(3) doi: 10.1136/jitc-2021-004029. PMID: 35277458Free PMC Article
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
Maitland ML, Sachdev JC, Sharma MR, Moreno V, Boni V, Kummar S, Stringer-Reasor E, Lakhani N, Moreau AR, Xuan D, Li R, Powell EL, Jackson-Fisher A, Bowers M, Alekar S, Xin X, Tolcher AW, Calvo E
Clin Cancer Res 2021 Aug 15;27(16):4511-4520. Epub 2021 Jun 3 doi: 10.1158/1078-0432.CCR-20-3757. PMID: 34083232Free PMC Article
"Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?
Davis A, Tinker AV, Friedlander M
Gynecol Oncol 2014 Jun;133(3):624-31. Epub 2014 Mar 4 doi: 10.1016/j.ygyno.2014.02.038. PMID: 24607285

Clinical prediction guides

Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.
Richardson DL, Eskander RN, O'Malley DM
JAMA Oncol 2023 Jun 1;9(6):851-859. doi: 10.1001/jamaoncol.2023.0197. PMID: 37079311
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lim PC, Castro CM, Provencher D, Memarzadeh S, Method M, Wang J, Moore KN, O'Malley DM
Gynecol Oncol 2023 Mar;170:241-247. Epub 2023 Feb 1 doi: 10.1016/j.ygyno.2023.01.020. PMID: 36736157
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
Maitland ML, Sachdev JC, Sharma MR, Moreno V, Boni V, Kummar S, Stringer-Reasor E, Lakhani N, Moreau AR, Xuan D, Li R, Powell EL, Jackson-Fisher A, Bowers M, Alekar S, Xin X, Tolcher AW, Calvo E
Clin Cancer Res 2021 Aug 15;27(16):4511-4520. Epub 2021 Jun 3 doi: 10.1158/1078-0432.CCR-20-3757. PMID: 34083232Free PMC Article
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, Konecny GE, Banerjee S, Murphy CG, Tanyi JL, Hirte H, Konner JA, Lim PC, Prasad-Hayes M, Monk BJ, Pautier P, Wang J, Berkenblit A, Vergote I, Birrer MJ
Ann Oncol 2021 Jun;32(6):757-765. Epub 2021 Mar 2 doi: 10.1016/j.annonc.2021.02.017. PMID: 33667670
Copy number signatures and mutational processes in ovarian carcinoma.
Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley LA, Hanif A, Wilson C, Dowson S, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Paul J, Supernat A, Millan D, Hoyle A, Bryson G, Nourse C, Mincarelli L, Sanchez LN, Ylstra B, Jimenez-Linan M, Moore L, Hofmann O, Markowetz F, McNeish IA, Brenton JD
Nat Genet 2018 Sep;50(9):1262-1270. Epub 2018 Aug 13 doi: 10.1038/s41588-018-0179-8. PMID: 30104763Free PMC Article

Recent systematic reviews

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
Gaitskell K, Rogozińska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J
Cochrane Database Syst Rev 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3. PMID: 37185961Free PMC Article
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A, Ryan N, Wiggans AJ, Rogozińska E, Morrison J
Cochrane Database Syst Rev 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4. PMID: 35170751Free PMC Article
Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation.
Staropoli N, Ciliberto D, Chiellino S, Caglioti F, Giudice TD, Gualtieri S, Salvino A, Strangio A, Botta C, Pignata S, Tassone P, Tagliaferri P
Oncotarget 2016 Dec 13;7(50):82741-82756. doi: 10.18632/oncotarget.12633. PMID: 27764790Free PMC Article
Overcoming platinum resistance in ovarian carcinoma.
Matsuo K, Lin YG, Roman LD, Sood AK
Expert Opin Investig Drugs 2010 Nov;19(11):1339-54. Epub 2010 Sep 6 doi: 10.1517/13543784.2010.515585. PMID: 20815774Free PMC Article
A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship.
Stordal B, Pavlakis N, Davey R
Cancer Treat Rev 2007 Dec;33(8):688-703. Epub 2007 Sep 18 doi: 10.1016/j.ctrv.2007.07.013. PMID: 17881133

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...